Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 7/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | SGK1 | O00141 | 3/20 | 0.38 |
| ▸ | S100A9 | P06702 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.36 |
| ▸ | EDNRA | P25101 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26980258 | 1.00 | CCR4 (0.45) | CCR4NR4A2SGK1S100A9MEN1 | |
| SCHEMBL30559623 | 0.89 | CCR4 (0.41) | CCR4NR4A2SGK1MEN1KMT2A | |
| SCHEMBL26980500 | 0.89 | CCR4 (0.41) | CCR4NR4A2SGK1MEN1KMT2A | |
| SCHEMBL26980371 | 0.88 | CCR4 (0.41) | CCR4NR4A2SGK1MEN1KMT2A | |
| SCHEMBL30559631 | 0.88 | CCR4 (0.41) | CCR4NR4A2SGK1MEN1KMT2A | |
| SCHEMBL26980246 | 0.88 | CCR4 (0.43) | CCR4NR4A2SGK1MEN1KMT2A | |
| SCHEMBL29903833 | 0.88 | CCR4 (0.43) | CCR4NR4A2SGK1MEN1KMT2A | |
| SCHEMBL30559620 | 0.86 | HTT (0.42) | CCR4NR4A2SGK1MEN1KMT2A | |
| SCHEMBL29903634 | 0.86 | CCR4 (0.40) | CCR4NR4A2SGK1MEN1KMT2A | |
| SCHEMBL26980728 | 0.86 | CCR4 (0.40) | CCR4NR4A2SGK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4298092-B1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | claimed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | GPR17, GPR27, GPR119 | CCR4 551/4885NR4A2 83/4885SGK1 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.